50jili logo
Cerity Partners LLC Increases Stake in AXIS Capital Holdings Limited (NYSE:AXS)( MENAFN - Jordan Times) AMMAN - The Vocational Training Corporation (VTC), in collaboration with German International Cooperation, launched on Sunday the second phase of its dual vocational training programme in Germany. This new phase follows the success of the first phase, which included three specialisations: electrical technician/renewable energy, bakery, and electric/hybrid vehicle maintenance, according to the Jordan News Agency, Petra. The second phase introduces 11 new training programmes aimed at broadening opportunities for young Jordanians, including: general electrician, car maintenance technician, refrigeration technology electrician, metal industries technician, health systems installation and maintenance technician, heating and air conditioning technician, carpenter, audiology technician, optics technician, dental technician, textile cleaning machine operator, baker, and pastry chef/confectioner. As part of the programme, proficiency in the German language at level A2 is a prerequisite, the VTC said, noting that the preparatory phase includes a five-month German language course up to level B1, delivered by accredited institutions, as well as career guidance sessions to prepare participants for careers in the skilled trades sector to be held in Jordan. Eligibility criteria for applicants include being a Jordanian citizen aged 18 to 34, holding at least a Grade 11 diploma, having a minimum of A2-level proficiency in German, and committing to a 3.5-year vocational training programme in Germany. The vocational training phase in Germany offers participants the opportunity to train at accredited vocational centres and gain hands-on experience with German private-sector companies. The programme follows Germany's renowned vocational training system and provides participants with a monthly stipend of at least 934 euros, health insurance throughout the duration of training, and an annual increase in stipend. To be eligible for the German phase, applicants must successfully complete the B1-level German language course, pass the necessary language exams, obtain an accredited B1 certificate, and secure a training position with a German company following interviews with employers. VTC Director-General Ahmad Gharaibeh stressed that the project, funded by the German Federal Ministry for Economic Cooperation and Development, is designed to provide young Jordanians with vocational training that leads to stable employment. The programme is part of the Partnerships for Development project on labour migration (PAM), which is implemented by German International Cooperation on behalf of the German Federal Ministry for Economic Cooperation and Development. It is carried out in partnership with the German Federation of Skilled Trades and the VTC. For more details and inquiries, the VTC invited interested individuals to contact the VTC's hotline at 0799958106 or to register via MENAFN15122024000028011005ID1108995665 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
EQT Corp director Karam sells $2.06 million in stock
500-year-old shipwreck could be São Jorge from Vasco da Gama’s final voyage
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE AmgenFollowing arguably the most dominant year of golf since Tiger Woods was in his prime, Scottie Scheffler received the PGA Tour Player of the Year award on Tuesday night. It's the third straight year Scheffler has won the honor, and the World No. 1 joins Woods as the only players to win the Jack Nicklaus Award three years in a row. The award is determined by a vote of PGA Tour members. According to a news release, Scheffler received 91 percent of the vote, with Xander Schauffele and Northern Ireland's Rory McIlroy the only other nominees. Scheffler, 28, was the first player to win seven official PGA Tour events in a calendar year since Tiger Woods in 2007. Those victories were at some of the most prestigious events on the schedule, against some of the most elite fields. He became the first player to go back-to-back at The Players Championship, won his second career major title at the Masters and earned his other five wins at signature events: the Arnold Palmer Invitational, the RBC Heritage, the Memorial Tournament, the Travelers Championship and the season-ending Tour Championship. Though not a tour event, Scheffler captured the Olympic gold medal for men's golf at the Paris Games. He also helped the United States defeat the International team at the Presidents Cup in Montreal. "Scottie took on challenges from the best players in the world on the biggest stages all season, and being honored as PGA Tour Player of the Year is the ultimate sign of respect from his peers," PGA Tour commissioner Jay Monahan said in a statement. --Field Level Media
- Previous: 50jili login register
- Next: 50jili me
